Core Insights - Amarin is undergoing a strategic pivot towards a partnered international commercial model and has executed a global restructuring to lower operating expenses, with 2025 being marked as a "substantial achievement" year [2] Group 1: Strategic Partnerships and Restructuring - The exclusive long-term partnership with Recordati, starting in Q3 2025, is a key driver for Amarin's operational review and restructuring initiative [3] - The license and supply agreement with Recordati covers 59 countries, focusing on Europe, and transfers European promotional activities to Recordati [3] - The agreement provides immediate financial value, including a $25 million upfront cash payment and potential future milestone payments up to $150 million, contingent on Recordati achieving $100 million in annual net sales [4] Group 2: Market Performance and Sales Dynamics - Early commercial indicators show growth in volume and demand in launch markets, particularly in Italy, where pricing and reimbursement have been secured [5] - In the U.S., VASCEPA has maintained market leadership among icosapent ethyl products five years post-generic launch, retaining major managed care exclusives through 2025 [6] - U.S. sales for Q4 2025 declined by 7% due to a decrease in net selling price, attributed to proactive pricing strategies [6]